Literature DB >> 25037737

Genomic and transcriptional alterations in lung adenocarcinoma in relation to smoking history.

Anna Karlsson1, Markus Ringnér1, Martin Lauss2, Johan Botling3, Patrick Micke3, Maria Planck1, Johan Staaf4.   

Abstract

PURPOSE: Cigarette smoking is the major pathogenic factor for lung cancer. The precise mechanisms of tobacco-related carcinogenesis and its effect on the genomic and transcriptional landscape in lung cancer are not fully understood. EXPERIMENTAL
DESIGN: A total of 1,398 (277 never-smokers and 1,121 smokers) genomic and 1,449 (370 never-smokers and 1,079 smokers) transcriptional profiles were assembled from public lung adenocarcinoma cohorts, including matched next-generation DNA-sequencing data (n = 423). Unsupervised and supervised methods were used to identify smoking-related copy-number alterations (CNAs), predictors of smoking status, and molecular subgroups.
RESULTS: Genomic meta-analyses showed that never-smokers and smokers harbored a similar frequency of total CNAs, although specific regions (5q, 8q, 16p, 19p, and 22q) displayed a 20% to 30% frequency difference between the two groups. Importantly, supervised classification analyses based on CNAs or gene expression could not accurately predict smoking status (balanced accuracies ∼60% to 80%). However, unsupervised multicohort transcriptional profiling stratified adenocarcinomas into distinct molecular subgroups with specific patterns of CNAs, oncogenic mutations, and mutation transversion frequencies that were independent of the smoking status. One subgroup included approximately 55% to 90% of never-smokers and approximately 20% to 40% of smokers (both current and former) with molecular and clinical features of a less aggressive and smoking-unrelated disease. Given the considerable intragroup heterogeneity in smoking-defined subgroups, especially among former smokers, our results emphasize the clinical importance of accurate molecular characterization of lung adenocarcinoma.
CONCLUSIONS: The landscape of smoking-related CNAs and transcriptional alterations in adenocarcinomas is complex, heterogeneous, and with moderate differences. Our results support a molecularly distinct less aggressive adenocarcinoma entity, arising in never-smokers and a subset of smokers. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 25037737     DOI: 10.1158/1078-0432.CCR-14-0246

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis.

Authors:  Hannah O'Farrell; Bryant Harbourne; Zimple Kurlawala; Yusuke Inoue; Amy L Nagelberg; Victor D Martinez; Daniel Lu; Min Hee Oh; Bradley P Coe; Kelsie L Thu; Romel Somwar; Stephen Lam; Wan L Lam; Arun M Unni; Levi Beverly; William W Lockwood
Journal:  J Thorac Oncol       Date:  2018-12-19       Impact factor: 15.609

2.  Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target.

Authors:  Domenico Galetta; Annamaria Catino; Andrea Misino
Journal:  Transl Lung Cancer Res       Date:  2016-02

3.  Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer.

Authors:  Anna Karlsson; Hans Brunnström; Kajsa Ericson Lindquist; Karin Jirström; Mats Jönsson; Frida Rosengren; Christel Reuterswärd; Helena Cirenajwis; Åke Borg; Per Jönsson; Maria Planck; Göran Jönsson; Johan Staaf
Journal:  Oncotarget       Date:  2015-09-08

4.  Identification of feature genes for smoking-related lung adenocarcinoma based on gene expression profile data.

Authors:  Ying Liu; Ran Ni; Hui Zhang; Lijun Miao; Jing Wang; Wenqing Jia; Yuanyuan Wang
Journal:  Onco Targets Ther       Date:  2016-12-07       Impact factor: 4.147

5.  Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma.

Authors:  Markus Ringnér; Johan Staaf
Journal:  Oncotarget       Date:  2016-08-16

6.  Histopathological Imaging⁻Environment Interactions in Cancer Modeling.

Authors:  Yaqing Xu; Tingyan Zhong; Mengyun Wu; Shuangge Ma
Journal:  Cancers (Basel)       Date:  2019-04-24       Impact factor: 6.639

7.  Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.

Authors:  Xibin Zhuang; Chao Zhao; Jiayu Li; Chunxia Su; Xiaoxia Chen; Shengxiang Ren; Xuefei Li; Caicun Zhou
Journal:  Cancer Med       Date:  2019-04-24       Impact factor: 4.452

8.  Multiple genome pattern analysis and signature gene identification for the Caucasian lung adenocarcinoma patients with different tobacco exposure patterns.

Authors:  Yan-Mei Dong; Li-da Qin; Yi-Fan Tong; Qi-En He; Ling Wang; Kai Song
Journal:  PeerJ       Date:  2020-01-30       Impact factor: 2.984

9.  Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.

Authors:  Tomoaki Naka; Yutaka Hatanaka; Katsuji Marukawa; Hiromi Okada; Kanako C Hatanaka; Jun Sakakibara-Konishi; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Tomoko Mitsuhashi; Yoshihiro Matsuno
Journal:  Diagn Pathol       Date:  2016-04-18       Impact factor: 2.644

10.  Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing.

Authors:  Rahul Nahar; Weiwei Zhai; Tong Zhang; Angela Takano; Alexis J Khng; Yin Yeng Lee; Xingliang Liu; Chong Hee Lim; Tina P T Koh; Zaw Win Aung; Tony Kiat Hon Lim; Lavanya Veeravalli; Ju Yuan; Audrey S M Teo; Cheryl X Chan; Huay Mei Poh; Ivan M L Chua; Audrey Ann Liew; Dawn Ping Xi Lau; Xue Lin Kwang; Chee Keong Toh; Wan-Teck Lim; Bing Lim; Wai Leong Tam; Eng-Huat Tan; Axel M Hillmer; Daniel S W Tan
Journal:  Nat Commun       Date:  2018-01-15       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.